
Conference Coverage
about 14 hours ago
Cefiderocol Holds Activity Against Resistant Pseudomonas in VAPabout 16 hours ago
Local vs Central Testing: What It Means for Ensitrelvir COVID-19 PEPLatest Content

Cystatin C, Creatinine eGFR Gap Flags Higher Mortality, HF Risk

Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty Say

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Most Patients With Psoriasis Screened Positive for PsA at One Dermatology Clinic

Obesity Care Ownership Shifts to Specialties That Win Coverage

Shorts










Center on Health Equity & Access
All News

An employer coalition's new guide outlines how workplaces can prevent and manage diabetes, from benefit design to accommodations.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.

Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer UTI agents.

New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.

An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM treatment.




























